PNC Financial Services Group
RPRX

PNC Financial Services Group’s Repros Therapeutics Inc. RPRX Stock Holding History

PNC Financial Services Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-175
Closed – – 4273
2016
Q3 		$0 Buy
+175
New +$346 ﹤0.01% 4732

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

PNC Financial Services Group's RPRX Position: Q4 2016 in Review

PNC Financial Services Group sold out of Repros Therapeutics Inc. (RPRX) in Q4 2016, closing a stake of 175 shares.

PNC Financial Services Group first reported a position in RPRX in Q3 2016 and held it in 1 quarter. The position peaked at $0 in Q3 2016. 43 funds tracked by Wall St. Rank hold RPRX as of Q4 2016.

  • PNC Financial Services Group reported no remaining Repros Therapeutics Inc. position as of Q4 2016 after selling out during the quarter.
  • PNC Financial Services Group sold 175 Repros Therapeutics Inc. shares in Q4 2016.
  • PNC Financial Services Group first reported a position in Repros Therapeutics Inc. in Q3 2016 and held it in 1 quarter.
  • PNC Financial Services Group's Repros Therapeutics Inc. position peaked at $0 in Q3 2016.
  • 43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2016.

Based on PNC Financial Services Group's 13F filing for Q4 2016, filed 10 Feb 2017.